Parkin & Synuclein
Home Up Anti P Acetylated & phosphorylated p63 P73 alpha and beta PACAP Pancreatic Polypeptide Paracellin-1 Parkin & Synuclein Parvalbumin/Oncomodulin PAS3/JAP3 PTX3 and NPX1-2 PHM Per1, Per2 &  Per 3 PHEX/PEX Pit-1/GLVR1 & Pit-2 PGHS-1 and 2 Podocin & Podocalyxin Potassium Chloride Cotrans. Pre-pro Orexin Pref-1,FA1, DLK1,ZOG Presenilin-1 Proline Transporter Prostaglandin-endoperox Prostaglandin E Receptor PGT PUMA/JFY1

 

 

 

Parkin & Synuclein (alpha, beta, and gamma) Antibodies

 

Parkinson's disease (PD) is a common neurodegenerative disorder with a lifetime incidence of approximately 2 percent; the clinical manifestations of this neurodegenerative disorder include resting tremor, muscular rigidity, bradykinesia, and postural instability. A relatively specific pathological feature accompanying the neuronal degeneration is an intracytoplasmic inclusion body, known as the Lewy body. A mutation was identified in the alpha synuclein gene, which codes for a presynaptic protein thought to be involved in neuronal plasticity, this mutation may cause a conformational change that renders alpha-synuclein more prone to self aggregation and deposition in Lewy bodies, which finally leads to oxidative stress and misfolding of alpha-synuclein.

Parkin gene, mutations in this gene are reported in early autosomal-recessive form of PD, however these mutations do not degenerate Lewy bodies. The Parkin gene product (Parkin) is involved in protein degradation as a ubiquitin protein ligase, the known substrates of Parkin include PAEL-R (Parkin-associated endothelin receptor-like receptor), Ubiquitination of Pael-R by Parkin leads to its degradation in the proteasome, however failure to ubiquitinate it leads to death of neuron.

Parkin is a 465aa protein in human (chr 6q25.2-q27) and mouse, expressed in many tissues, including brain, heart, testis, and skeletal muscle. In the brain, Parkin is expressed in various regions including substantia nigra.

Alzheimer's Disease (AD) is another neurodegenerative disorder characterized by progressive loss of memory and cognition in the elderly, One of the most important and initial step involves proteolytic cleavage of amyloid precursor protein releasing short 40, 42 & 43 aa peptides, the deposits of these short peptides has been found to contain anti-chymotrypsin (ACT), Apolipoprotein (Apo-E) and two additional proteins named alpha-synuclein and beta-synuclein.

The synuclein exists in 3 isoform alpha-syn (chrm 4q21), a 140aa protein, implicated in pathogenesis of PD and related neurodegenerative disorders, it is mainly expressed in brain specifically in neuronal cell bodies and synapses. The 134 aa beta-syn (chrm 5q35) is homologous to 14 kDa bovine phosphoneuroprotein 14; SCNB has shown to be highly expressed in the substantia nigra of the brain. Recently a new isoform termed gamma-synuclein (SNCG) or breast cancer gene 1 (BCG1) has been cloned (human 127 aa (chrm 10q23), rat/mouse 123 aa). Higher levels of expression of SNCG have been reported in advanced breast carcinomas. All three synuclein show ~40% identity.

Publications on Parkin and Synuclein-alpha using ADI's Antibodies:

Parkin, Hase A et al 2002 Brain Res. 930, 143-149 Characterization of parkin in bovine peripheral nerve.
 

Synuclein-alpha, Sudo S et al 2002 Acta Neuropathologica DOI 10.1007 Motor neuron disease with dementia combined with degeneration of striatonigral and pallidoluysian systems.

 Items

Antigen peptide location 

 Antibody Host

 Expected Ab Crossreactivity * 

Aff. Pure IgG/Mab
Cat #
100 ug

 * Control Peptide Cat#
100 ug

Parkin (Ab # 1)

H, 23 aa, CT

Rb

m, r, h

PARK11-A

PARK11-P

Parkin isoform 2
(Ab # 2)
Prakin isoform 2
Protein
G, poly H PARK12-A  

a-synuclein (Ab #1)

H, 16 aa

Rb

m, r, h

SYN11-A

SYN11-P

a-synuclein (Ab #2)

R, 19 aa

Rb

r, m

SYN12-A

SYN12-A

a-synuclein
(Ab #3)

Human alpha Syn protein m, mono H (m, r?)

SYN16-M

 

a-synuclein (P#1)

H, alp-syn

Human Alpha-Synuclein, Purified Recombinant Protein Cat # SYN-25R (50 ug) 

W.blot +ve protein control SYN11-C(100ul)

a-synuclein (P#2)

H, alp-syn

Human Alpha-Synuclein, Purified Recombinant Protein Cat # SYN-A30P-R (50 ug)

a-synuclein (P#3)

H, alp-syn

Human Alpha-Synuclein, Purified Recombinant Protein Cat # SYN-A53T-R (50 ug)

a-synuclein 

(Protein #3)

H, alp-syn, mutant A53T

Alpha-Synuclein, Purified Recombinant Protein Cat # SYN-A53T-R (50 ug)

 a-synuclein
(Protein # 4)

H, alp-syn mutant A30P/A53T

Alpha-Synuclein, Recombinant double mutant Protein Cat # SA3053T-R (50ug)

a-synuclein
(Protein # 5)

H, alp-syn deletion mutant (61-95)

Alpha-Synuclein, Recombinant deletion mutant Protein Cat # SD6195-R (25ug)

a-synuclein
(Protein # 6)

H, alp-syn deletion mutant (61-140)

Alpha-Synuclein, Recombinant deletion mutant Protein Cat # SD61140-R (25ug)

a-synuclein
(Protein # 7)

H, alp-syn deletion mutant (96-140)

Alpha-Synuclein, Recombinant deletion mutant Protein Cat # SD96140-R (25ug)

b-synuclein (Ab #1)

H, 14 aa

 Rb

 m, h, r

 SYN13-A

SYN13-P

b-synuclein

(Protein #1)

H, beta-syn

Beta-Synuclein, Recombinant protein (134aa) Cat # SYN-25R (50 ug)
Beta-Synuclein, W.blot +ve protein control SYN13-C (100 ul)

g-synuclein (Ab #1)

M, 18 aa CT

 Rb

 r, m

SYN14-A

SYN14-P

g-synuclein (Ab #2)

 H, 17 aa CT

Rb

h

SYN15-A

SYN15-P

g-synuclein (P#1)

 H, g-syn

Human Gamma-Synuclein, Purified Recombinant Protein Cat # SYN-35R (50 ug) 

W.blot +ve protein control SYN15-C(100ul)



m=mouse; r=rat; h=human; b=bovine; d=dog; ~CT or ~NT=near C or N-terminus. EC=Extracellular; CP=Cytoplasmic domain;

* Expected antibody crossreactivity information is mostly based upon high (>70%) sequence conservation of antigenic/control peptides in various species. When antibody crossreactivity has actually been experimentally confirmed in various species, it will be mentioned in the appropriate data sheets.

"Neat Antisera or antisera" are the unpurified antiserum and it is suitable for ELISA and Western.
"Affinity pure" IgG may be more suitable for immunohistochemical (IHC) applications and to reduce background in most immunological applications including ELISA and Western.
"Control peptides" can not be used for Western as they are very short peptides. They are intended for ELISA or antibody blocking studies to establish antibody specificity.
Western blot +ve protein controls, where available, are semi-pure, pure or recombinant proteins that are formulated in SDS-PAGE sample buffer (reduced). They are recommended to be used for Western (load 10 ul/lane) for visualization with antibodies.

All Products are for in vitro research use only.